

# Amanda McCann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8096283/publications.pdf>

Version: 2024-02-01

70  
papers

3,180  
citations

172207

29  
h-index

155451

55  
g-index

73  
all docs

73  
docs citations

73  
times ranked

5574  
citing authors

#	ARTICLE	IF	CITATIONS
1	The potential role of cofilin-1 in promoting triple negative breast cancer (TNBC) metastasis via the extracellular vesicles (EVs). <i>Translational Oncology</i> , 2022, 15, 101247.	1.7	12
2	Has the National Fall in Smoking Rates in Ireland Been Replicated in Cancer Patients? A 5-Year Report. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2348.	1.2	2
3	A comparative analysis of extracellular vesicles (EVs) from human and feline plasma. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
4	N-Linked glycosylation profiles of therapeutic induced senescent (TIS) triple negative breast cancer cells (TNBC) and their extracellular vesicle (EV) progeny. <i>Molecular Omics</i> , 2021, 17, 72-85.	1.4	12
5	5-AZA-dC induces epigenetic changes associated with modified glycosylation of secreted glycoproteins and increased EMT and migration in chemo-sensitive cancer cells. <i>Clinical Epigenetics</i> , 2021, 13, 34.	1.8	11
6	The role of von Willebrand factor in breast cancer metastasis. <i>Translational Oncology</i> , 2021, 14, 101033.	1.7	18
7	“Could you give us an idea on what we are all doing here?” the Patient Voice in Cancer Research (PVCR) starting the journey of involvement in Ireland. <i>Research Involvement and Engagement</i> , 2021, 7, 63.	1.1	4
8	Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling. <i>Leukemia</i> , 2020, 34, 196-209.	3.3	48
9	Too MAD or not MAD enough: The duplicitous role of the spindle assembly checkpoint protein MAD2 in cancer. <i>Cancer Letters</i> , 2020, 469, 11-21.	3.2	18
10	Exosomes in triple negative breast cancer: Garbage disposals or Trojan horses?. <i>Cancer Letters</i> , 2020, 473, 90-97.	3.2	43
11	Exosomes as Biomarkers of Human and Feline Mammary Tumours; A Comparative Medicine Approach to Unravelling the Aggressiveness of TNBC. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188431.	3.3	15
12	Hypoxia Alters Epigenetic and N-Glycosylation Profiles of Ovarian and Breast Cancer Cell Lines in-vitro. <i>Frontiers in Oncology</i> , 2020, 10, 1218.	1.3	20
13	HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells. <i>Cancers</i> , 2020, 12, 3734.	1.7	22
14	Circulating Melanoma-Derived Extracellular Vesicles: Impact on Melanoma Diagnosis, Progression Monitoring, and Treatment Response. <i>Pharmaceuticals</i> , 2020, 13, 475.	1.7	13
15	The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer. <i>PLoS ONE</i> , 2020, 15, e0243715.	1.1	7
16	The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer. , 2020, 15, e0243715.		0
17	The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer. , 2020, 15, e0243715.		0
18	The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer. , 2020, 15, e0243715.		0

#	ARTICLE	IF	CITATIONS
19	The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer. , 2020, 15, e0243715.		0
20	Clarifying the mechanisms and resources that enable the reciprocal involvement of seldom heard groups in health and social care research: A collaborative rapid realist review process. Health Expectations, 2019, 22, 298-306.	1.1	39
21	Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis. Cancers, 2019, 11, 66.	1.7	73
22	Overcoming multiple myeloma drug resistance in the era of cancer "omics"™. Leukemia and Lymphoma, 2018, 59, 542-561.	0.6	34
23	BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer. Oncotarget, 2018, 9, 15673-15690.	0.8	22
24	Resident bacteria in breast cancer tissue: pathogenic agents or harmless commensals?. Discovery Medicine, 2018, 26, 93-102.	0.5	8
25	A Protocol for Improved Precision and Increased Confidence in Nanoparticle Tracking Analysis Concentration Measurements between 50 and 120%nm in Biological Fluids. Frontiers in Cardiovascular Medicine, 2017, 4, 68.	1.1	48
26	The association between MAD2 and prognosis in cancer: a systematic review and meta-analyses. Oncotarget, 2017, 8, 102223-102234.	0.8	9
27	Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and ovarian cancer. Epigenetics, 2016, 11, 845-857.	1.3	39
28	The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clinical, 2015, 3, 257-275.	4.1	293
29	Anxiety is associated with higher levels of global DNA methylation and altered expression of epigenetic and interleukin-6 genes. Psychiatric Genetics, 2015, 25, 71-78.	0.6	72
30	Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells. Cancer Medicine, 2015, 4, 745-758.	1.3	132
31	The MyD88+ Phenotype Is an Adverse Prognostic Factor in Epithelial Ovarian Cancer. PLoS ONE, 2014, 9, e100816.	1.1	36
32	Raman spectroscopy and SERS analysis of ovarian tumour derived exosomes (TEXs): a preliminary study. , 2014, , .		6
33	Lipofuscin accumulation and autophagy in glaucomatous human lamina cribrosa cells. BMC Ophthalmology, 2014, 14, 153.	0.6	22
34	Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype. Human Molecular Genetics, 2014, 23, 2176-2188.	1.4	235
35	Spindle assembly checkpoint protein expression correlates with cellular proliferation and shorter time to recurrence in ovarian cancer. Human Pathology, 2014, 45, 1509-1519.	1.1	16
36	Low MAD2 protein expression is a predictor of poor outcome after chemotherapy and radiotherapy in oestrogen receptor negative breast cancer patients. European Journal of Surgical Oncology, 2013, 39, S76.	0.5	0

#	ARTICLE	IF	CITATIONS
37	Commentary on paper: 5-Aza-2'-deoxycytidine increases sialyl Lewis X on MUC1 by stimulating $\beta$ -2,3-sialyltransferase 6 gene (Chachadi et al.). International Journal of Biochemistry and Cell Biology, 2012, 44, 737.	1.2	2
38	Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer. Journal of Pathology, 2012, 226, 746-755.	2.1	64
39	Homocysteine levels impact directly on epigenetic reprogramming in astrocytes. Neurochemistry International, 2011, 58, 833-838.	1.9	13
40	Epigenetic Effect of Cadmium on Global De Novo DNA Hypomethylation in the Cadmium-Induced Ventral Body Wall Defect (VBWD) in the Chick Model. Toxicological Sciences, 2011, 120, 475-480.	1.4	64
41	Alpha T-catenin (CTNNA3): a gene in the hand is worth two in the nest. Cellular and Molecular Life Sciences, 2011, 68, 2493-2498.	2.4	18
42	5-AZA-2'-deoxycytidine induced demethylation influences N-glycosylation of secreted glycoproteins in ovarian cancer. Epigenetics, 2011, 6, 1362-1372.	1.3	63
43	The Epithelium: Molecular Landscaping for an Interactive Barrier. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-1.	3.0	7
44	MAD2 downregulation in hypoxia is independent of promoter hypermethylation. Cell Cycle, 2010, 9, 2928-2937.	1.3	9
45	Epigenetics: The epicenter of the hypoxic response. Epigenetics, 2010, 5, 293-296.	1.3	157
46	MAD2 downregulation in hypoxia is independent of promoter hypermethylation. Cell Cycle, 2010, 9, 2856-65.	1.3	7
47	Generation of an epigenetic signature by chronic hypoxia in prostate cells. Human Molecular Genetics, 2009, 18, 3594-3604.	1.4	94
48	Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro. British Journal of Cancer, 2009, 101, 1900-1908.	2.9	44
49	Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder. BJU International, 2009, 103, 694-697.	1.3	10
50	Progesterone receptor B (PRB) promoter hypermethylation in sporadic breast cancer. Breast Cancer Research and Treatment, 2008, 111, 45-53.	1.1	17
51	Taxanes, microtubules and chemoresistant breast cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2008, 1785, 96-132.	3.3	313
52	Small Interfering RNAs Induce Macrophage Migration Inhibitory Factor Production and Proliferation in Breast Cancer Cells via a Double-Stranded RNA-Dependent Protein Kinase-Dependent Mechanism. Journal of Immunology, 2008, 180, 7125-7133.	0.4	32
53	Recurrence of Urothelial Carcinoma of the Bladder: A Role for Insulin-Like Growth Factor-II Loss of Imprinting and Cytoplasmic E-Cadherin Immunolocalization. Clinical Cancer Research, 2008, 14, 6829-6838.	3.2	11
54	Molecular Basis for Estrogen Receptor $\beta$ Deficiency in BRCA1-Linked Breast Cancer. Journal of the National Cancer Institute, 2007, 99, 1683-1694.	3.0	183

#	ARTICLE	IF	CITATIONS
55	CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. <i>International Journal of Cancer</i> , 2007, 120, 1434-1443.	2.3	98
56	Alpha-T-catenin (CTNNA3) displays tumour specific monoallelic expression in urothelial carcinoma of the bladder. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 587-593.	1.5	12
57	Imprinted expression of the canine <i>IGF2R</i> , in the absence of an anti-sense transcript or promoter methylation. <i>Evolution &amp; Development</i> , 2007, 9, 579-589.	1.1	22
58	Gain of imprinting of SLC22A18 sense and antisense transcripts in human breast cancer. <i>Genomics</i> , 2006, 88, 12-17.	1.3	34
59	A Multi-Centre Investigation Towards Reaching a Consensus on the Immunohistochemical Detection of ER $\beta$ in Archival Formalin-fixed Paraffin Embedded Human Breast Tissue. <i>Breast Cancer Research and Treatment</i> , 2005, 92, 287-293.	1.1	45
60	Elevated expression and altered processing of fibulin-1 protein in human breast cancer. <i>British Journal of Cancer</i> , 2003, 88, 871-878.	2.9	68
61	Promoter switch: a novel mechanism causing biallelic PEG1/MEST expression in invasive breast cancer. <i>Human Molecular Genetics</i> , 2002, 11, 1449-1453.	1.4	44
62	The MAS Proto-oncogene Is Imprinted in Human Breast Tissue. <i>Genomics</i> , 1997, 46, 509-512.	1.3	24
63	Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. <i>British Journal of Cancer</i> , 1995, 71, 981-985.	2.9	100
64	Prognostic significance of microvessel density in lymph node negative breast carcinoma. <i>Human Pathology</i> , 1995, 26, 1181-1184.	1.1	113
65	Argyrophilic nucleolar organiser regions (AgNORs) as a prognostic indicator in breast carcinoma. <i>Irish Journal of Medical Science</i> , 1992, 161, 112-115.	0.8	5
66	Irish association for cancer research. <i>Irish Journal of Medical Science</i> , 1991, 160, 116-126.	0.8	0
67	c-erbB-2 oncoprotein expression in primary human tumors. <i>Cancer</i> , 1990, 65, 88-92.	2.0	137
68	Non-M CK is a practical measure of creatine kinase isoenzymes in cancer patients. <i>Clinica Chimica Acta</i> , 1990, 187, 309-315.	0.5	8
69	c-erbB-2 oncoprotein expression in malignant and nonmalignant breast tissue. <i>Irish Journal of Medical Science</i> , 1989, 158, 137-140.	0.8	12
70	What are the mechanisms that enable the reciprocal involvement of seldom heard groups in health and social care research? A rapid realist review protocol. <i>HRB Open Research</i> , 0, 1, 7.	0.3	13